BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-5104 [PMID: 31558859 DOI: 10.3748/wjg.v25.i34.5097] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu L, Nahata MC. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Ann Pharmacother 2023;:10600280221149708. [PMID: 36688309 DOI: 10.1177/10600280221149708] [Reference Citation Analysis]
2 Kamal A, Ghazy RM, Sherief D, Ismail A, Ellakany WI. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial. BMC Infect Dis 2023;23:36. [PMID: 36670359 DOI: 10.1186/s12879-023-07993-8] [Reference Citation Analysis]
3 Wang YZ, Chen J, Pei SQ, Wang C, Han G, Kan LD, Li LC. Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug Dev Res 2022. [PMID: 36567647 DOI: 10.1002/ddr.22025] [Reference Citation Analysis]
4 Petrov VI, Ponomareva AV, Ivakhnenko IV, Razvalyaeva OV, Dotsenko AM. PROBLEMS OF ERADICATION THERAPY AND WAYS TO OVERCOME THEM: R EVIEW OF MODERN RECOMMENDATIONS AND REAL PRACTICE. Journal of Volgograd State Medical University 2022;19:22-33. [DOI: 10.19163/1994-9480-2022-19-4-22-33] [Reference Citation Analysis]
5 Assalin HB, De Almeida KCG, Guadagnini D, Santos A, Teixeira CJ, Bordin S, Rocha GZ, Saad MJA. Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver. Int J Mol Sci 2022;23. [PMID: 36430244 DOI: 10.3390/ijms232213766] [Reference Citation Analysis]
6 Xu X, He C, Zhu Y. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Front Microbiol 2022;13:998240. [DOI: 10.3389/fmicb.2022.998240] [Reference Citation Analysis]
7 Gudra D, Silamikelis I, Pjalkovskis J, Danenberga I, Pupola D, Skenders G, Ustinova M, Megnis K, Leja M, Vangravs R, Fridmanis D. Development and use of an ESBL coding gene panel in patients undergoing first-line eradication therapy for Helicobacter pylori.. [DOI: 10.21203/rs.3.rs-2080077/v1] [Reference Citation Analysis]
8 Karcioglu O, Yeniocak S, Hosseinzadeh M, Bahar Sezgin S. Specific Diagnoses and Management Principles of the Upper Digestive Canal. Abdominal Pain: Essential Diagnosis and Management in Acute Medicine 2022. [DOI: 10.2174/9789815051780122010005] [Reference Citation Analysis]
9 Reyes D, Ortiz J, Fuentes-lópez E, Budnik S, Gándara V, Gallardo A, Seydewitz MF, Candia R, Vargas JI, Rollan MP, Godoy J, Rollan A, Mansilla R, Arenas A, Chahuán J, Espino A, Pizarro M, Riquelme A. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterología y Hepatología (English Edition) 2022;45:515-523. [DOI: 10.1016/j.gastre.2022.07.004] [Reference Citation Analysis]
10 Shi X, Wang C, Meng F, Ma S, Xu G, Liu T, Guo X, Li H, Qi X. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgrad Med 2022. [PMID: 35860966 DOI: 10.1080/00325481.2022.2105094] [Reference Citation Analysis]
11 Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Tratamiento empírico vs tratamiento basado en susceptibilidad para erradicar H.pylori: ¿es posible cambiar este paradigma usando métodos moleculares modernos? Revista de Gastroenterología de México 2022;87:330-341. [DOI: 10.1016/j.rgmx.2022.01.007] [Reference Citation Analysis]
12 Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? Revista de Gastroenterología de México (English Edition) 2022;87:330-341. [DOI: 10.1016/j.rgmxen.2022.06.003] [Reference Citation Analysis]
13 Pranantyo D, Zhang K, Si Z, Hou Z, Chan-Park MB. Smart Multifunctional Polymer Systems as Alternatives or Supplements of Antibiotics To Overcome Bacterial Resistance. Biomacromolecules 2022. [PMID: 35471022 DOI: 10.1021/acs.biomac.1c01614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Losurdo G, Lacavalla I, Russo F, Riezzo G, Brescia IV, Rendina M, Ierardi E, Di Leo A. Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. Antibiotics (Basel) 2022;11:78. [PMID: 35052955 DOI: 10.3390/antibiotics11010078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Argueta EA, Moss SF. How We Approach Difficult to Eradicate Helicobacter pylori. Gastroenterology 2022;162:32-7. [PMID: 34743914 DOI: 10.1053/j.gastro.2021.10.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Yadollahi B, Valizadeh Toosi SM, Bari Z, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Kazemi A, Shokri-Afra H. Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy on H. pylori eradication. Gastroenterol Hepatol Bed Bench 2022;15:172-8. [PMID: 35845300] [Reference Citation Analysis]
17 Reyes D, Ortiz J, Fuentes-López E, Budnik S, Gandara V, Gallardo A, Seydewitz MF, Candia R, Ignacio Vargas J, Rollan MP, Godoy J, Rollan A, Mansilla R, Arenas A, Chahuán J, Espino A, Pizarro M, Riquelme A. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterol Hepatol 2021:S0210-5705(21)00320-4. [PMID: 34890721 DOI: 10.1016/j.gastrohep.2021.11.010] [Reference Citation Analysis]
18 Ghazvini K, Kamali H, Hosseininasab-nodoushan S, Keikha M. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021;25:101340. [DOI: 10.1016/j.genrep.2021.101340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kasza K, Gurnani P, Hardie KR, Cámara M, Alexander C. Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account. Adv Drug Deliv Rev 2021;178:113973. [PMID: 34530014 DOI: 10.1016/j.addr.2021.113973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Jonaitis P, Kupcinskas J, Nyssen OP, Puig I, Gisbert JP, Jonaitis L. Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina (Kaunas) 2021;57:642. [PMID: 34201428 DOI: 10.3390/medicina57070642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Correia ACP, Straub D, Calpe S, Krishnadath KK. Novel In Vivo Mouse Cryoablation Model to Explore Unique Therapeutic Approaches for Premalignant Columnar Lesions. Methods Protoc 2021;4:6. [PMID: 33526760 DOI: 10.3390/mps4010006] [Reference Citation Analysis]
26 Huang Q, Shi Z, Cheng H, Ye H, Zhang X. Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials. J Clin Gastroenterol 2021;55:856-64. [PMID: 33074949 DOI: 10.1097/MCG.0000000000001448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Muñoz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol 2020;11:549084. [PMID: 33281754 DOI: 10.3389/fmicb.2020.549084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bai Z, Ding N, Ge J, Wang Y, Wang L, Wu N, Wei Q, Xu S, Liu X, Zhou G. Esomeprazole overcomes paclitaxel-resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells. Cell Biol Int 2021;45:177-87. [PMID: 33049093 DOI: 10.1002/cbin.11481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
29 Park H, Kim CO, Kim M, Lim Y, Lee WY, Yoon S, Park MS. Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Transl Clin Pharmacol 2020;28:136-46. [PMID: 33062627 DOI: 10.12793/tcp.2020.28.e16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
31 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
32 O'Connor A, Furuta T, Gisbert JP, O'Morain C. Review - Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25 Suppl 1:e12743. [PMID: 32918350 DOI: 10.1111/hel.12743] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
33 Ierardi E, Losurdo G, Mileti A, Paolillo R, Giorgio F, Principi M, Di Leo A. The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science.Antibiotics (Basel). 2020;9. [PMID: 32486473 DOI: 10.3390/antibiotics9060293] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]